Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinsons Disease Treatment will Boost Market Despite Patent Cliff

Published: Mar-2013 | Format: PDF | GBI Research | Code: MRS - 1313

GBI Research, the leading business intelligence provider, has released its latest research “Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinson’s Disease Treatment will Boost Market Despite Patent Cliff”. A highly dynamic market scenario is expected in Neurodegenerative diseases in the next few years, with a number of patent expiries and anticipated new drug approvals. The market for Alzheimer’s disease has not seen any recent major breakthroughs, and is expected to experience a decline due to the patent expiry of several major products. 

The market for Parkinson’s disease, on the other hand, is expected to experience growth due to the anticipated approval of expensive products such as Duodopa in the US, in spite of the fact that it will soon hit its own patent cliff. Additionally, the overall aging of populations the developed world is expected to increase the number of patients suffering from these diseases due to their relatively high prevalence in the elderly.

Scope

  • The current therapeutic environment in the treatment of AD, PD, HD and ALS across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan.
  • Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations.
  • Market forecasts for all four indications across the US, the top five countries in Europe (EU5) - Germany, France, the UK, Italy, and Spain- as well as Japan.
  • Key market drivers and barriers
  • The major deals that have taken place in the Neurodegenerative Diseases Market in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total value. A concomitant analysis of the licensing deal values for products by molecule types and is also provided.


Reasons to Buy

  • Understand the competitive environment for Neurodegenerative Diseases
  • Understand the clinical and commercial impact of major patent expiries in the neurodegenerative diseases markets
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the neurodegenerative diseases market in the forecast period
  • Grasp the unmet need which exists in the neurodegenerative diseases Market
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Neurodegenerative Diseases Market to 2018: Introduction
2.1 GBI Research Report Guidance

3 Neurodegenerative Diseases Market to 2018: Global Market Overview
3.1 Revenue
3.2 Treatment Usage Pattern
3.3 Distribution by Market
3.4 Drivers and Restraints of the Neurodegenerative Diseases Market
3.4.1 Drivers
3.4.2 Restraints

4 Therapeutic Landscape
4.1 Market for Alzheimer’s Disease
4.1.1 Introduction
4.1.2 Revenue and Forecasts
4.1.3 Treatment Usage Pattern
4.1.4 Geographical Landscape
4.1.5 Drivers and Restraints for the Alzheimer’s Disease Market
4.2 Market for Parkinson’s Disease
4.2.1 Introduction
4.2.2 Revenue and Forecasts
4.2.3 Treatment Usage Pattern
4.2.4 Geographical Landscape
4.2.5 Drivers and Restraints for the Parkinson’s Disease Market
4.3 Market for Amyotrophic Lateral Sclerosis
4.3.1 Introduction
4.3.2 Revenue and Forecasts
4.3.3 Treatment Usage Pattern
4.3.4 Geographical Landscape
4.3.5 Drivers and Restraints for the Amyotrophic Lateral Sclerosis Market
4.4 Market for Huntington’s Disease
4.4.1 Introduction
4.4.2 Revenue and Forecasts
4.4.3 Treatment Usage Pattern
4.4.4 Geographical Landscape
4.4.5 Drivers and Restraints for the Huntington’s Disease Market

5 Neurodegenerative Diseases Market: Pipeline Analysis
5.1 Introduction
5.2 Summary of the Current Neurodegenerative Diseases R&D Pipeline
5.2.1 Alzheimer's Disease
5.2.2 Amyotrophic Lateral Sclerosis
5.2.3 Parkinson’s Disease
5.2.4 Huntington’s Disease

6 Neurodegenerative Diseases Market: Deals and Strategic Consolidations
6.1 Merger and Acquisition Deals
6.1.1 Sanofi-Synthelabo Merges with Aventis
6.1.2 Bayer Acquires Schering
6.1.3 Takeda Pharma Completes Acquisition of Nycomed International for $13,681m
6.1.4 Teva Pharma Acquires Ivax
6.1.5 Abbott Labs Acquires Solvay Pharma
6.1.6 Teva Completes Acquisition of Cephalon for $6.8 billion
6.1.7 UCB Acquires 87.62% Stake in Schwarz Pharma
6.1.8 Biovail Acquires Valeant Pharma
6.1.9 Dainippon Sumitomo Pharma Completes Acquisition of Sepracor for $2.6 Billion
6.1.10 Merck Acquires Banyu Pharma
6.1.11 Amgen Completes Acquisition of Micromet for $1.2 Billion
6.1.12 Bayer Acquires Minority Stake in Bayer Schering Pharma
6.1.13 Daiichi Sankyo Completes Acquisition of Plexxikon
6.1.14 Lundbeck Acquires Ovation Pharma
6.1.15 Eli Lilly and Company Acquires Avid RadioPharma
6.1.16 Abbott Labs Completes Acquisition of Facet Biotech
6.1.17 Biogen Idec Acquires Fumapharm
6.1.18 Upsher-Smith Completes Acquisition of Remaining 84% Stake in Proximagen for up to $555m
6.1.19 Sun Pharma Acquires Controlling Stake in Taro Pharma
6.1.20 Pfizer Acquires Rinat Neuroscience
6.1.21 Cubist Pharma Completes Acquisition of Adolor for $415m
6.1.22 Biogen Idec Acquires Panima Pharma
6.1.23 Teva Pharma Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey
6.1.24 Fujifilm Holdings Acquires 66% Stake in Toyama Chemical
6.1.25 MGI PHARMA Acquires Guilford Pharma
6.1.26 H. Lundbeck Acquires LifeHealth
6.1.27 Endo Pharma Completes Acquisition of Penwest Pharma
6.1.28 EPIX Pharma Acquires Predix Pharma
6.1.29 Biogen Idec Acquires Syntonix Pharmaceuticals
6.1.30 Biotie Therapies Acquires Synosia Therapeutics
6.2 Licensing Agreements
6.2.1 Cephalon Enters into a Licensing Agreement with Mesoblast for Regenerative Medicine
6.2.2 Idera Pharma Enters into a Licensing Agreement with Merck
6.2.3 Astellas Pharma Enters into Licensing Agreement with CoMentis for Beta-Secretase Inhibitors
6.2.4 Synosia Therapeutics Enters into Licensing Agreement with UCB for SYN-115 and SYN-118
6.2.5 GlaxoSmithKline Signs an Agreement with AFFiRiS
6.2.6 Biogen Enters into an Agreement with Acorda Therapeutics
6.2.7 BioMS Medical Enters into Licensing Agreement with Eli Lilly
6.2.8 AC Immune Enters into Licensing Agreement with Genentech for Anti-Tau Antibodies
6.2.9 Biovail Enters into Licensing Agreement with Acadia Pharmaceuticals
6.2.10 Biogen Idec Enters into Licensing Agreement with Knopp Neurosciences for KNS-760704
6.2.11 AstraZeneca Enters into Licensing Agreement with Targacept
6.2.12 AC Immune Enters into Licensing Agreement with Genentech
6.2.13 Proximagen Enters into Licensing Agreement with Upsher-Smith Labs
6.2.14 Merck Serono Enters into Licensing Agreement with Apitope Technology
6.2.15 Serono Enters into Licensing Agreement with Newron Pharma for Safinamide
6.2.16 Shire Exercises Option to License Adenosine A2A from Heptares Therapeutics
6.2.17 GlaxoSmithKline Enters into Licensing Agreement with Impax Pharma for IPX066
6.2.18 Santhera Pharmaceuticals Enters into Licensing Agreement with Ipsen for Fipamezole
6.2.19 Domain Therapeutics Enters into Licensing Agreement with Merck Serono
6.2.20 Addex Pharma Enters into Collaboration and Licensing Agreement with Merck & Co
6.2.21 Curis Enters into Licensing Agreement with Wyeth Pharma
6.2.22 Pfizer Enters into a License and Collaboration Agreement with Transtech Pharma
6.2.23 Antisense Therapeutics Enters into Licensing Agreement with Teva Pharma
6.2.24 Biogen Idec Enters into Licensing Agreement with Vernalis
6.3 Co-Development Deals
6.3.1 GlaxoSmithKline Signs an Agreement with Targacept
6.3.2 GlaxoSmithKline Enters into an Agreement with EPIX Pharma
6.3.3 Evotec Enters into Co-Development Agreement with Roche
6.3.4 Pfizer Enters into Co-Development Agreement with Medivation for Dimebon
6.3.5 Alectos Therapeutics Enters into Research Collaboration with Merck & Co
6.3.6 Targacept Expands its Collaboration Agreement with AstraZeneca
6.3.7 Boehringer Ingelheim Partners with Vitae Pharma
6.3.8 Elan Enters into Co-Development Agreement with Transition Therapeutics
6.3.9 Ceregene Enters into Agreement with Genzyme

7 Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Sources
7.4 Research Methodology
7.4.1 Coverage
7.4.2 Secondary Research
7.4.3 Primary Research
7.5 Therapeutic Landscape
7.5.1 Epidemiology-based Forecasting
7.5.2 Market Size by Geography
7.6 Geographical Landscape
7.7 Pipeline Analysis
7.8 Competitive Landscape
7.8.1 Expert Panel Validation
7.9 Contact Us
7.10 Disclaimer

List of Tables

Table 1: Neurodegenerative Diseases Market, Global, Revenue Forecast ($m), 2012–2018
Table 2: Neurodegenerative Diseases Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Table 3: Neurodegenerative Diseases Market, Global, Treatment Usage Pattern (’000), 2012–2018
Table 4: Neurodegenerative Diseases Market, Global, Revenue Forecast by Market ($m), 2012–2018
Table 5: Alzheimer’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Table 6: Alzheimer’s Disease Market, Global, Treatment Usage Pattern (‘000), 2012–2018
Table 7: Alzheimer’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Table 8: Alzheimer’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Table 9: Alzheimer’s Disease Market, US, Annual Cost of Therapy ($), 2012–2018
Table 10: Alzheimer’s Disease Market, US, Treatment Usage Pattern (‘000), 2012–2018
Table 11: Alzheimer’s Disease Market, UK, Revenue Forecast ($m), 2012–2018
Table 12: Alzheimer’s Disease Market, UK, Annual Cost of Therapy ($), 2012–2018
Table 13: Alzheimer’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Table 14: Alzheimer’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Table 15: Alzheimer’s Disease Market, France, Annual Cost of Therapy ($), 2012–2018
Table 16: Alzheimer’s Disease Market, France, Treatment Usage Pattern (‘000), 2012–2018
Table 17: Alzheimer’s Disease Market, Germany, Revenue Forecast ($m), 2012–2018
Table 18: Alzheimer’s Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018
Table 19: Alzheimer’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Table 20: Alzheimer’s Disease Market, Italy, Revenue Forecast ($m), 2012–2018
Table 21: Alzheimer’s Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018
Table 22: Alzheimer’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Table 23: Alzheimer’s Disease Market, Spain, Revenue Forecast ($m), 2012–2018
Table 24: Alzheimer’s Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018
Table 25: Alzheimer’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012–2018
Table 26: Alzheimer’s Disease Market, Japan, Revenue Forecast ($m), 2012–2018
Table 27: Alzheimer’s Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018
Table 28: Alzheimer’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Table 29: Parkinson’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Table 30: Parkinson’s Disease Market, Global, Treatment Usage Pattern (‘000), 2012–2018
Table 31: Parkinson’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Table 32: Parkinson’s Disease Market, US, Revenue Forecast ($m), 2012–2018
Table 33: Parkinson’s Disease Market, US, Annual Cost of Therapy ($), 2012–2018
Table 34: Parkinson’s Disease Market, US, Treatment Usage Pattern (‘000), 2012–2018
Table 35: Parkinson’s Disease Market, UK, Revenue Forecast ($m), 2012–2018
Table 36: Parkinson’s Disease Market, UK, Annual Cost of Therapy ($), 2012–2018
Table 37: Parkinson’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Table 38: Parkinson’s Disease Market, France, Revenue Forecast ($m), 2012–2018
Table 39: Parkinson’s Disease Market, France, Annual Cost of Therapy ($), 2012–2018
Table 40: Parkinson’s Disease Market, France, Treatment Usage Pattern (‘000), 2012–2018
Table 41: Parkinson’s Disease Market, Germany, Revenue Forecast ($m), 2012–2018
Table 42: Parkinson’s Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018
Table 43: Parkinson’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Table 44: Parkinson’s Disease Market, Italy, Revenue Forecast ($m), 2012–2018
Table 45: Parkinson’s Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018
Table 46: Parkinson’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Table 47: Parkinson’s Disease Market, Spain, Revenue Forecast ($m), 2012–2018
Table 48: Parkinson’s Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018
Table 49: Parkinson’s Disease Market, Spain, Treatment Usage Pattern Forecast (‘000), 2012–2018
Table 50: Parkinson’s Disease Market, Japan, Revenue Forecast ($m), 2012–2018
Table 51: Parkinson’s Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018
Table 52: Parkinson’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Table 53: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast ($m), 2012–2018
Table 54: Amyotrophic Lateral Sclerosis Market, Global, Treatment Usage Pattern (‘000), 2010–2018
Table 55: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Table 56: Amyotrophic Lateral Sclerosis Market, US, Revenue Forecast ($m), 2012–2018
Table 57: Amyotrophic Lateral Sclerosis Market, US, Annual Cost of Therapy ($), 2012–2018
Table 58: Amyotrophic Lateral Sclerosis Market, US, Treatment Usage Pattern (‘000), 2012–2018
Table 59: Amyotrophic Lateral Sclerosis Market, UK, Revenue Forecast ($m), 2012–2018
Table 60: Amyotrophic Lateral Sclerosis Market, UK, Annual Cost of Therapy ($), 2012–2018
Table 61: Amyotrophic Lateral Sclerosis Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Table 62: Amyotrophic Lateral Sclerosis Market, France, Revenue Forecast ($m), 2012–2018
Table 63: Amyotrophic Lateral Sclerosis Market, France, Annual Cost of Therapy ($), 2012–2018
Table 64: Amyotrophic Lateral Sclerosis Market, France, Treatment Usage Pattern (‘000), 2012–2018
Table 65: Amyotrophic Lateral Sclerosis Market, Germany, Revenue Forecast ($m), 2012–2018
Table 66: Amyotrophic Lateral Sclerosis Market, Germany, Annual Cost of Therapy ($), 2012–2018
Table 67: Amyotrophic Lateral Sclerosis Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Table 68: Amyotrophic Lateral Sclerosis Market, Italy, Revenue Forecast ($m), 2012–2018
Table 69: Amyotrophic Lateral Sclerosis Market, Italy, Annual Cost of Therapy ($), 2012–2018
Table 70: Amyotrophic Lateral Sclerosis Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Table 71: Amyotrophic Lateral Sclerosis Market, Spain, Revenue Forecast ($m), 2012–2018
Table 72: Amyotrophic Lateral Sclerosis Market, Spain, Annual Cost of Therapy ($), 2012–2018
Table 73: Amyotrophic Lateral Sclerosis Market, Spain, Treatment Usage Pattern (‘000), 2012–2018
Table 74: Amyotrophic Lateral Sclerosis Market, Japan, Revenue Forecast ($m), 2012–2018
Table 75: Amyotrophic Lateral Sclerosis Market, Japan, Annual Cost of Therapy ($), 2012–2018
Table 76: Amyotrophic Lateral Sclerosis Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Table 77: Huntington’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Table 78: Huntington’s Disease Market, Global, Treatment Usage Pattern (‘000), 2012–2018
Table 79: Huntington’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Table 80: Huntington’s Disease Market, US, Revenue Forecast ($m), 2012–2018
Table 81: Huntington’s Disease Market, US, Annual Cost of Therapy ($), 2012–2018
Table 82: Huntington’s Disease Market, US, Treatment Usage Pattern (‘000), 2012–2018
Table 83: Huntington’s Disease Market, UK, Revenue Forecast ($m), 2012–2018
Table 84: Huntington’s Disease Market, UK, Annual Cost of Therapy ($), 2012–2018
Table 85: Huntington’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Table 86: Huntington’s Disease Market, France, Revenue Forecast ($m), 2012–2018
Table 87: Huntington’s Disease Market, France, Annual Cost of Therapy ($), 2012–2018
Table 88: Huntington’s Disease Market, France, Treatment Usage Pattern (‘000), 2012–2018
Table 89: Huntington’s Disease Market, Germany, Revenue Forecast ($m), 2012–2018
Table 90: Huntington’s Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018
Table 91: Huntington’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Table 92: Huntington’s Disease Market, Italy, Revenue Forecast ($m), 2012–2018
Table 93: Huntington’s Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018
Table 94: Huntington’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Table 95: Huntington’s Disease Market, Spain, Revenue Forecast ($m), 2012–2018
Table 96: Huntington’s Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018
Table 97: Huntington’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012–2018
Table 98: Huntington’s Disease Market, Japan, Revenue Forecast ($m), 2012–2018
Table 99: Huntington’s Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018
Table 100: Huntington’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Table 101: Neurodegenerative Diseases Market, Global, Alzheimer’s Disease Product Pipeline, 2012
Table 102: Neurodegenerative Diseases Market, Global, Amyotrophic Lateral Sclerosis Product Pipeline, 2012
Table 103: Neurodegenerative Diseases Market, Global, Parkinson’s Disease Product Pipeline, 2012
Table 104: Neurodegenerative Diseases Market, Global, Huntington’s Disease Product Pipeline, 2012

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3500 View Pricing